Tofacitinib overcomes an IFNγ‐induced decrease in NK cell‐mediated cytotoxicity via the regulation of immune‐related molecules in LC‐2/ad

BACKGROUND: Immune checkpoint inhibitors targeting the programmed cell death‐1 (PD‐1)/PD‐1 ligand 1 (PD‐L1) axis have shown promising results in patients with nonsmall cell lung cancer (NSCLC). One major PD‐L1 inducer is IFNγ, which is secreted by T cells and NK cells. Importantly, IFNγ‐induced PD‐L...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Thorac Cancer
Egile Nagusiak: Okita, Riki, Shimizu, Katsuhiko, Nojima, Yuji, Saisho, Shinsuke, Nakata, Masao
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons Australia, Ltd 2021
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7952785/
https://ncbi.nlm.nih.gov/pubmed/33491334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13847
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak